Recently, T cell engager molecule targeting DLL3, tarlatamab, has been FDA approved for SCLC, and antibody-drug conjugates (ADCs) have been shown to have antitumor activity against SCLC in early trials [128]. Here, DLL3 is linked to small cell lung carcinoma.